Concepedia

Author

Ferdinando De Vita

University of Campania "Luigi Vanvitelli"ORCID

Also Known As

De Vita, Ferdinando, F De Vita, F VITA, F. De Vita, F. de Vita, FERDINANDO DE VITA, Ferdinando DE Vita, Ferdinando De Vita, Ferdinando De Vita (337845), Ferdinando De vita

345

Publications

10K

Citations

53

H-Index

86

Concepts

All Affiliations

University of Campania "Luigi Vanvitelli"University of Naples Federico IIIstituti di Ricovero e Cura a Carattere ScientificoIstituto Nazionale Tumori IRCCS "Fondazione G. Pascale"Casa Sollievo della Sofferenza
FD

About

Ferdinando De Vita is an author at University of Campania "Luigi Vanvitelli" specializing in medicine, oncology, and pathology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

31

51

3.5K

2

Health Sciences

4

4

179

3

Cell Biology

2

2

41

4

Natural Sciences

1

1

11

5

Epidemiology

1

1

51

Ferdinando De Vita

×

126

Publications

7.2K

Citations

46

H-Index

YearCitations

Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials

Joseph Chao, Charles S. Fuchs, Kohei Shitara,

JAMA Oncology

2021

415

Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy

Fortunato Ciardiello, Roberto Bianco, Roberta Caputo,

Clinical Cancer Research

2004

346

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial

Daniel V.T. Catenacci, Niall C. Tebbutt, André M. Murad,

The Lancet Oncology

2017

338

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Charles S. Fuchs, Kohei Shitara, Maria Di Bartolomeo,

The Lancet Oncology

2019

276

Expression of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) is an Independent Prognostic Indicator of Worse Outcome in Gastric Cancer Patients

Eva Lieto, Francesca Ferraraccio, Michele Orditura,

Annals of Surgical Oncology

2007

238

Prognostic Significance of Circulating IL-10 and IL-6 Serum Levels in Colon Cancer Patients Undergoing Surgery

Gennaro Galizia, Michele Orditura, Ciro Romano,

Clinical Immunology

2002

230

A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients

Ferdinando De Vita, Michele Orditura, Elide Matano,

British Journal of Cancer

2005

180

Epidermal Growth Factor Receptor (EGFR) Expression is Associated With a Worse Prognosis in Gastric Cancer Patients Undergoing Curative Surgery

Gennaro Galizia, Eva Lieto, Michele Orditura,

World Journal of Surgery

2007

148

MicroRNA-423-5p Promotes Autophagy in Cancer Cells and Is Increased in Serum From Hepatocarcinoma Patients Treated With Sorafenib

Paola Stiuso, Nicoletta Potenza, Angela Lombardi,

Molecular Therapy — Nucleic Acids

2015

145

HER2 loss in HER2‐positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research

Filippo Pietrantonio, M. Caporale, Federica Morano,

International Journal of Cancer

2016

142

Page 1